Diabetes is reaching epidemic proportions. Each year millions of people join the ranks of the victims. So with this hope is found every new invention in medicine and pharmacology, which can make life easier for patients diabetes, to improve their health and reduce the number of expensive medications prescribed for daily administration. Last year, the patented one of these life-saving tools – glyukostab. Patented it in Ukraine, and there is. Recently held a presentation glyukostaba and Russia – at the Center for healing and rejuvenation of man.
Clinical studies were conducted in Nikopol Dnipropetrovsk region. Five hundred patients diabetes first and second types have taken a new drug and were followed for 7 months. Positive changes in the patient are impressive even skeptical physicians: improved vision, healing venous ulcers, the overall normalization of the illness, not counting the actual reduction and stabilization of blood glucose. In patients not previously treated with any antidiabetic drugs, there is practically immediate results: the level of sugar in the blood decreases after 20 minutes after the first drop glyukostaba. If the insulin or glucose-lowering drugs were taken for several years, a visible effect on the reception glyukostaba seen in a few days. Glyukostab not only lowers blood sugar levels, but also stabilizes it. The ability to keep the rate of glucose in the blood – one of the most important benefits of a new drug, but not only.
Glyukostab capable of compensating measures glucose in the blood within the normal range 3.3 – 5.5 mg / dL. The drug is absolutely non-toxic and compatible with other drugs. No side effects have been identified. Glyukostab positive effect on metabolism, not only by the carbohydrate level, but also in terms of lipid metabolism. Lowers LDL cholesterol and VLDL in hypercholesterolemia. Glyukostab improves the flow properties of blood, which is especially important for patients suffering from obesity, hypertension, hyperlipidemia and other conditions often accompany diabetes Type II diabetes.